The FDA has approved the first combination to treat chronic hepatitis C (HCV) infection that does not require co-administration with interferon or ribavirin. Harvoni (ledipasvir and sofosbuvir) treats genotype 1 HCV.
Backed by 6 drug firms and 4 foundations, the National Institutes of Health has created a large network of top researchers charged wtih collaborating to comprehend lupus and rheumatoid arthritis at the cellular and molecular level.
Neurological symptoms may be the presenting feature in lupus, sarcoidosis, vasculitis, and other rheumatic diseases, notes this review. Treatment may also cause neurological side effects including demyelination, tremor, and psychosis.